Zobrazeno 1 - 10
of 41
pro vyhledávání: '"RC254-282"'
Autor:
Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran, Elias Jabbour, Guillermo Garcia-Manero, Ghayas C. Issa, Guillermo Montalban-Bravo, Musa Yilmaz, Abhishek Maiti, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-10 (2022)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is uncertai
Autor:
Hengyu Li, Pinghua Yang, JingHan Wang, Jin Zhang, Qianyun Ma, Yingjie Jiang, Yani Wu, Tao Han, Daimin Xiang
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Tumor-associated macrophages (TAMs) are major components of the tumor microenvironment (TME) which are closely associated with the tumor malignant progression. However, the regulatory mechanisms by which TAMs influence the progression of triple-negat
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-19 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
The use of immune checkpoint blockade (ICB) using antibodies against programmed death receptor (PD)-1, PD ligand (PD-L)-1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) has redefined the therapeutic landscape in solid tumors, including skin, lung, bl
Autor:
Maria Volkova, Pavel Borisov, Ilya Tsimafeyeu, Sergey Savchuk, Vadim Goutnik, Alexander Nosov, Andrey Semenov, Natalia Dengina, Ruslan Zukov, Igor Myslevtsev, Galina Alekseeva, Maria Berkut, Timur Mitin, Andrey Andrianov
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-7 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with genitourinary (GU) malignancies. Aim of our analysis was to describe the characteristics of the COVID-1
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology and Oncology
Journal of Hematology and Oncology, BioMed Central, 2021, 14 (1), ⟨10.1186/s13045-021-01172-5⟩
Journal of Hematology and Oncology, 2021, 14 (1), ⟨10.1186/s13045-021-01172-5⟩
Journal of Hematology & Oncology
Journal of Hematology and Oncology
Journal of Hematology and Oncology, BioMed Central, 2021, 14 (1), ⟨10.1186/s13045-021-01172-5⟩
Journal of Hematology and Oncology, 2021, 14 (1), ⟨10.1186/s13045-021-01172-5⟩
Journal of Hematology & Oncology
Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantama
Autor:
Yu-Lung Lau, Alan Kwok Shing Chiang, Daniel Ka Leung Cheuk, Alex Wing Kwan Leung, Wing Leung, Marco Ho, Shau Yin Ha, Ian C. K. Wong, Janette Kwok, Godfrey Chi-Fung Chan, P Ip, Wai Keung Chu, Jaime S. Rosa Duque, Chun Wing Luk, Alvin Siu-Cheung Ling, Wilfred Hing Sang Wong, Y.S. Chan, Gilbert T. Chua, Chi Kong Li, Anthony P.Y. Liu, Pamela P. W. Lee, Mike Yat Wah Kwan, Oscar Kuen Fong Yiu
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Asparaginase is an important drug to treat childhood haematological malignancies. Data on the association between human leukocyte antigens (HLA) and asparaginase hypersensitivity among Chinese are lacking. We conducted a retrospective study to identi
Autor:
Frederic Peyrade, Graham P. Collins, Yihua Lee, Jutta K. Neuenburg, Michael Wang, Robert T. Chen, Geoffrey Chong, Karl Eckert, Constantine S. Tam, Radhakrishnan Ramchandren, Lionel Karlin, Ka Lung Wu, Mark Bishton, Paul Eliadis, Wojciech Jurczak
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer
Autor:
Tahk, Siret, Vick, Binje, Hiller, Björn, Schmitt, Saskia, Marcinek, Anetta, Perini, Enrico D., Leutbecher, Alexandra, Augsberger, Christian, Reischer, Anna, Tast, Benjamin, Humpe, Andreas, Jeremias, Irmela, Subklewe, Marion, Fenn, Nadja C., Hopfner, Karl-Peter
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-17 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting with myeloid-specific signa
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-18 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR/ABL protein, which is encoded by the bcr/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the wide application of tyrosine kinase inhibito
Autor:
Jianhua Zhong, Hamid Sayar, Dominik Selleslag, Christopher Pocock, C.L. Beach, Farhad Ravandi, Rochelle Bailey, Pau Montesinos, Angela Figuera-Alvarez, Sang Kyun Sohn, Andrew H. Wei, Hervé Dombret, William Tse, Hartmut Döhner, Francesca Pierdomenico, Maurizio Musso, Gail J. Roboz, Timothy Chevassut, Hana Safah, Devendra K Hiwase, Ignazia La Torre, Barry S. Skikne
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)
JOURNAL OF HEMATOLOGY & ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of Hematology & Oncology
JOURNAL OF HEMATOLOGY & ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of Hematology & Oncology
Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine mai